Desmopressin for bleeding in non-severe hemophilia A: Suboptimal use in a real-world setting.

ABSTRACT:

Background

Desmopressin is an important treatment option in nonsevere hemophilia A because it has several benefits compared with factor (F) concentrates, including no inhibitor risk and much lower costs. Despite these advantages, data are limited on the real-world use of desmopressin in the treatment of bleeds.

Objective

To describe the clinical use of desmopressin in relation to other therapeutic modalities in the treatment of bleeding episodes in patients with nonsevere hemophilia A.

Methods

Patients with nonsevere hemophilia A aged 12-55 years were included from the DYNAMO cohort study. Data on the desmopressin test response and treated bleeding events in the period January 2009 to July 2020 were retrospectively collected from medical files. An adequate desmopressi

SUBMITTER: Zwagemaker AF 

PROVIDER: S-EPMC9433315 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature